Cargando…

A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant

Detalles Bibliográficos
Autores principales:	Liu, Zezhong, Chan, Jasper Fuk-Woo, Zhou, Jie, Wang, Meiyu, Wang, Qian, Zhang, Guangxu, Xu, Wei, Chik, Kenn Ka-Heng, Zhang, Yilong, Wang, Youchun, Yuen, Kwok-Yung, Lu, Lu, Jiang, Shibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866927/ https://www.ncbi.nlm.nih.gov/pubmed/35210607 http://dx.doi.org/10.1038/s41422-022-00631-z

Ejemplares similares

A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs
por: Liu, Zezhong, et al.
Publicado: (2022)

A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates
por: Liu, Zezhong, et al.
Publicado: (2023)

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
por: Xia, Shuai, et al.
Publicado: (2022)

A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern
por: Lan, Qiaoshuai, et al.
Publicado: (2022)

Superimmunity by pan-sarbecovirus nanobodies
por: Xiang, Yufei, et al.
Publicado: (2022)

An interferon-integrated mucosal vaccine provides pan-sarbecovirus protection in small animal models
por: Yuen, Chun-Kit, et al.
Publicado: (2023)

Up or down: where comes Omicron?
por: Liu, Zezhong, et al.
Publicado: (2022)

Pan-sarbecovirus mAb protects from variants
por: Flemming, Alexandra
Publicado: (2021)

Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies
por: Zhang, Fengwen, et al.
Publicado: (2023)

Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination
por: Adams, Lily E., et al.
Publicado: (2023)

Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine
por: Coléon, Séverin, et al.
Publicado: (2022)

Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents
por: Cao, Yunlong, et al.
Publicado: (2022)

Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses
por: Wang, Yingdan, et al.
Publicado: (2022)

Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit
por: Hurlburt, Nicholas K., et al.
Publicado: (2022)

Differential escape of neutralizing antibodies by SARS-CoV-2 Omicron and pre-emergent sarbecoviruses
por: Wang, Lin-Fa, et al.
Publicado: (2022)

Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses
por: Li, Qianqian, et al.
Publicado: (2022)

Antibody evasion properties of SARS-CoV-2 Omicron sublineages
por: Iketani, Sho, et al.
Publicado: (2022)

Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity
por: Jensen, Jaime L., et al.
Publicado: (2023)

An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses
por: Liu, Lihong, et al.
Publicado: (2022)

Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors
por: Tan, Chee-Wah, et al.
Publicado: (2021)

The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage
por: Liang, Ronghui, et al.
Publicado: (2022)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

Isolation of Bat Sarbecoviruses, Japan
por: Murakami, Shin, et al.
Publicado: (2022)

Targeting SUMO Modification of the Non-Structural Protein 5 of Zika Virus as a Host-Targeting Antiviral Strategy
por: Zhu, Zheng, et al.
Publicado: (2019)

A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases
por: Zhou, Jie, et al.
Publicado: (2022)

A comprehensive dataset of animal-associated sarbecoviruses
por: Liu, Bo, et al.
Publicado: (2023)

Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor
por: Chia, Wan Ni, et al.
Publicado: (2023)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
por: Xia, Shuai, et al.
Publicado: (2023)

1899. The Cellular Kinase Inhibitor OSU-03012 Inhibits Enterovirus 71 In Vitro
por: Chan, Jasper, et al.
Publicado: (2018)

Peptidic defective interfering gene nanoparticles against Omicron, Delta SARS-CoV-2 variants and influenza A virus in vivo
por: Zhao, Hanjun, et al.
Publicado: (2022)

The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2018)

hnRNP C modulates MERS-CoV and SARS-CoV-2 replication by governing the expression of a subset of circRNAs and cognitive mRNAs
por: Zhang, Xi, et al.
Publicado: (2022)

Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2022)

Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants
por: Zhao, Hanjun, et al.
Publicado: (2022)

Pan-primate studies of age and sex
por: Horvath, Steve, et al.
Publicado: (2023)

A Multitrait Locus Regulates Sarbecovirus Pathogenesis
por: Schäfer, Alexandra, et al.
Publicado: (2022)

A trifunctional peptide broadly inhibits SARS-CoV-2 Delta and Omicron variants in hamsters
por: Zhao, Hanjun, et al.
Publicado: (2022)

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
por: Wang, Xinling, et al.
Publicado: (2023)

Priming conditions shape breadth of neutralizing antibody responses to sarbecoviruses
por: Jia, Janice Zhirong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0astl25p365hhq89ua24q35kl8